Last reviewed · How we verify
Tuberculin purified protein derivative
Tuberculin purified protein derivative, marketed by Assiut University, is a diagnostic tool primarily used for the detection of M. tuberculosis infection. The drug's key strength lies in its well-established mechanism for identifying TB infections, supported by a key composition patent that expires in 2028. The primary risk is the lack of revenue data and key trial results, which may limit its market visibility and competitive positioning.
At a glance
| Generic name | Tuberculin purified protein derivative |
|---|---|
| Sponsor | Assiut University |
| Drug class | Skin Test Antigen [EPC] |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
- Detection of M. tuberculosis infection
- PPD-tuberculin skin test in HIV-infected persons
Common side effects
- Erythema
- Pruritus
- Edema
- Rash
- Urticaria
- Pain
- Discomfort
- Immediate erythematous reactions
Serious adverse events
- Anaphylaxis
- Anaphylactoid reactions
- Vesiculation
- Ulceration
- Necrosis
- Scarring
- Angioedema
Drug interactions
- corticosteroids
- immunosuppressive agents
- live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella)
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
- The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis (NA)
- Online Transdiagnostic Group CBT for Postpartum Depression and Anxiety (NA)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy (PHASE1)
- BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tuberculin purified protein derivative CI brief — competitive landscape report
- Tuberculin purified protein derivative updates RSS · CI watch RSS
- Assiut University portfolio CI